Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

204 ARTÍCULOS , VIENDO DEL 121 AL 135

Fluid biomarker-based molecular phenotyping of Alzheimer's disease patients in research and clinical settings

Blennow K, Zetterberg H.

Prog Mol Biol Transl Sci. 2019;168:3-23. doi: 10.1016/bs.pmbts.2019.07.006. Epub 2019 Jul 24.

The Potential Emergence of Disease-Modifying Treatments for Alzheimer Disease: The Role of Primary Care in Managing the Patient Journey

Lam J, Hlávka J, Mattke S.

J Am Board Fam Med. 2019 Nov-Dec;32(6):931-940. doi: 10.3122/jabfm.2019.06.180328.

Genetic Markers of Alzheimer's Disease

Nikolac Perkovic M, Pivac N.

Adv Exp Med Biol. 2019;1192:27-52. doi: 10.1007/978-981-32-9721-0_3.

Macroalgae as a Valuable Source of Naturally Occurring Bioactive Compounds for the Treatment of Alzheimer's Disease

Olasehinde TA, Olaniran AO, Okoh AI.

Mar Drugs. 2019 Oct 25;17(11):609. doi: 10.3390/md17110609.

Neutral Endopeptidase (Neprilysin) in Therapy and Diagnostics: Yin and Yang

Feygina EE, Katrukha AG, Semenov AG.

Biochemistry (Mosc). 2019 Nov;84(11):1346-1358. doi: 10.1134/S0006297919110105.

Functional Connectivity in Neurodegenerative Disorders: Alzheimer's Disease and Frontotemporal Dementia

Jalilianhasanpour R, Beheshtian E, Sherbaf G, Sahraian S, Sair HI.

Top Magn Reson Imaging. 2019 Dec;28(6):317-324. doi: 10.1097/RMR.0000000000000223.

Oxidative Damage of DNA as Early Marker of Alzheimer's Disease

Peña-Bautista C, Tirle T, López-Nogueroles M, Vento M, Baquero M, Cháfer-Pericás C.

Int J Mol Sci. 2019 Dec 5;20(24):6136. doi: 10.3390/ijms20246136.

A cerebrospinal fluid biosignature for the diagnosis of Alzheimer's disease

Barichello T, Giridharan VV, Dal-Pizzol F.

Braz J Psychiatry. 2019 Nov-Dec;41(6):467-468. doi: 10.1590/1516-4446-2019-0629.

Dementia is not synonymous with Alzheimer's disease

Jack CR Jr, Holtzman DM, Sperling R.

Sci Transl Med. 2019 Dec 11;11(522):eaav0511. doi: 10.1126/scitranslmed.aav0511.

Cerebrospinal fluid and blood Aβ levels in Down syndrome patients with and without dementia: a meta-analysis study

Du Y, Chen L, Jiao Y, Cheng Y.

Aging (Albany NY). 2019 Dec 20;11(24):12202-12212. doi: 10.18632/aging.102560. Epub 2019 Dec 20.

Biomarkers for Alzheimer's disease. Where we stand and where we are headed

Chrem Mendez P, Surace E, Bérgamo Y, Calandri I, Vázquez S, Sevlever G, Allegri RF.

Medicina (B Aires). 2019;79(Spec 6/1):546-551.

CSF biomarkers of neuroinflammation in distinct forms and subtypes of neurodegenerative dementia

Abu-Rumeileh S, Steinacker P, Polischi B, Mammana A, Bartoletti-Stella A, Oeckl P, Baiardi S, Zenesini C, Huss A, Cortelli P, Capellari S, Otto M, Parchi P.

Alzheimers Res Ther. 2019 Dec 31;12(1):2. doi: 10.1186/s13195-019-0562-4.

Exosomes and microRNAs: New potential therapeutic candidates in Alzheimer disease therapy

Iranifar E, Seresht BM, Momeni F, Fadaei E, Mehr MH, Ebrahimi Z, Rahmati M, Kharazinejad E, Mirzaei H.

J Cell Physiol. 2019 Mar;234(3):2296-2305. doi: 10.1002/jcp.27214. Epub 2018 Sep 7.

CD33 in Alzheimer's Disease - Biology, Pathogenesis, and Therapeutics: A Mini-Review

Zhao L.

Gerontology. 2019;65(4):323-331. doi: 10.1159/000492596. Epub 2018 Dec 12.

Mass spectrometry is a multifaceted weapon to be used in the battle against Alzheimer's disease: Amyloid beta peptides and beyond

Grasso G.

Mass Spectrom Rev. 2019 Jan;38(1):34-48. doi: 10.1002/mas.21566. Epub 2018 Jun 15.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias